APROBARBITAL

US Previously Marketed

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H14N2O3
Molecular Weight	210.2298
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C1(CC=C)C(=O)NC(=O)NC1=O

InChI

InChIKey=UORJNBVJVRLXMQ-UHFFFAOYSA-N

InChI=1S/C10H14N2O3/c1-4-5-10(6(2)3)7(13)11-9(15)12-8(10)14/h4,6H,1,5H2,2-3H3,(H2,11,12,13,14,15)

HIDE SMILES / InChI

Description
Sources: https://www.drugs.com/mmx/aprobarbital.html

Aprobarbital is a barbiturate derivative. Aprobarbital have been used for the short-term treatment of insomnia and for routine sedation to relieve anxiety, tension, and apprehension however, barbiturates generally have been replaced by benzodiazepines.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABA-A receptor; anion channel 202 Target ID: CHEMBL2093872 Sources: https://www.drugbank.ca/drugs/DB01352	Positive Allosteric Modulator 179

Conditions

Condition	Modality	Targets	Highest Phase	Product
Insomnia 108 Sources: https://www.drugs.com/mmx/aprobarbital.html	Primary		Approved 8429	ALURATE Approved Use Aprobarbital have been used for the short-term treatment of insomnia and for routine sedation to relieve anxiety, tension, and apprehension however, barbiturates generally have been replaced by benzodiazepines. Launch Date 1927
Anxiety 267 Sources: https://www.drugs.com/mmx/aprobarbital.html	Primary		Approved 8429	ALURATE Approved Use Aprobarbital have been used for the short-term treatment of insomnia and for routine sedation to relieve anxiety, tension, and apprehension however, barbiturates generally have been replaced by benzodiazepines. Launch Date 1927

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:2791	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:2791
ZINC	ZINC000018167382	http://zinc15.docking.org/substances/ZINC000018167382
eMolecules	3715659	https://www.emolecules.com/cgi-bin/more?vid=3715659

PubMed

Title	Date	PubMed
Permanent impairment of renal function after methicillin nephropathy.	1971 Nov 13	5124441
Determination of zidovudine/lamivudine/nevirapine in human plasma using ion-pair HPLC.	2002 Jun 1	12039632
Determinations of zidovudine/didanosine/nevirapine and zidovudine/didanosine/ritonavir in human serum by micellar electrokinetic chromatography.	2002 Nov 7	12408885
Determination of lamivudine/stavudine/efavirenz in human serum using liquid chromatography/electrospray tandem mass spectrometry with ionization polarity switch.	2002 Sep	12228894
The history of barbiturates a century after their clinical introduction.	2005 Dec	18568113
Occurrence and fate of barbiturates in the aquatic environment.	2006 Dec 1	17180967

Patents

Sample Use Guides

In Vivo Use Guide

Usual adult dose Hypnotic: Oral, 40 to 160 mg at bedtime. Sedative: Daytime—Oral, 40 mg three times a day.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

APROBARBITAL

Official Name

English

APROBARBITAL [MI]

Common Name

English

5-ALLYL-5-ISOPROPYLBARBITURIC ACID

Systematic Name

English

NSC-120769

Code

English

Aprobarbital [WHO-DD]

Common Name

English

APROBARBITAL [MART.]

Common Name

English

APROBARBITAL [HSDB]

Common Name

English

ALURATE

Brand Name

English

APROBARBITAL [VANDF]

Common Name

English

aprobarbital [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C67084